Kosj Yamoah MD, PhD

@MoffittNews Chair and Professor, Department of Radiation Oncology. Director, RO Cancer Health Disparities Research. Views are my own.

[Kosj Yamoah MD, PhD @KOSJ12]

What an incredible day celebrating the ribbon-cutting at the @MoffittNews Speros Outpatient Center. I’m thrilled to showcase our Richard M. Schulze Family Foundation Proton Therapy Center, which will bring highly precise proton therapy to patients and expand access to care!

[Moffitt Cancer Center @MoffittNews]

Thank you to everyone who joined us for our #ASCO26 reception. It was a great opportunity to connect with colleagues and industry partners while celebrating the impactful research and innovation presented by Moffitt experts. We’re proud to be part of the work advancing cancer care and improving outcomes for patients worldwide. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

What new approaches are being explored to improve treatment for high-risk melanoma? Ahmad Tarhini, MD, PhD (@ATarhiniMDPhD), will present research at #ASCO26 evaluating a combination immunotherapy approach in high-risk resectable melanoma. #MoffittASCO26 @ASCO

[Moffitt Cancer Center @MoffittNews]

https://t.co/ig7DCxK2DS

[Moffitt Cancer Center @MoffittNews]

Day 3 of #ASCO26 is here! Join Moffitt experts as they share the latest advances in cancer research and care. Stop by booth #14012 to connect with our team and explore a full list of presentations at https://t.co/BK9OdLjCMd. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

Happening live at #ASCO26, Lilit Karapetyan, MD (@KarapetLilit), moderates an Oral Abstract Session focused on immunotherapy research, where experts share findings, discuss clinical implications and explore future directions in cancer care. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

What can real-world treatment patterns tell us about outcomes in myelofibrosis? Andrew Kuykendall, MD (@KuykendallMd), will share research at #ASCO26 exploring overall survival and evolving treatment approaches in relapsed or refractory myelofibrosis. #MoffittASCO26 @ASCO

[Moffitt Cancer Center @MoffittNews]

Live from #ASCO26: Tian Zhang, MD (@TiansterZhang, @UTSWCancer), highlighted how antibody-drug conjugates are transforming bladder cancer treatment and creating new opportunities for patients.

Key takeaways:
• ADC combination enfortumab vedotin
(EV)-pembrolizumab is now standard first-line treatment for metastatic disease.

• EV-pembrolizumab resistance poses clinical challenge. Nectin-4 remains a target but further characterization needed.

• ADC combinations coming into neoadjuvant/perioperative settings for local muscle-invasive bladder cancer.

#MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

What role could AI play in supporting cancer care decisions? Ariosto Silva, MD, will share research at #ASCO26 exploring a modular AI framework designed to provide interpretable, patient-specific oncology support. #MoffittASCO26 @ASCO

[Moffitt Cancer Center @MoffittNews]

Happening now at #ASCO26: Stephanie Lheureux, MD (@StephanieLheur5, @pmcancercentre), highlights emerging advances in ovarian cancer, including immunotherapies, glucocorticoid receptor antagonists and antibody-drug conjugates.

Key factors shaping the future of care include tumor biology, patient selection and treatment sequencing.

#MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

During Sunday morning's poster session at #ASCO26, Caitlyn Balsay-Patel, MD (@caitlynbalsay), shares research comparing treatment approaches for melanoma in-transit metastases, from regional and systemic therapies to individualized treatment considerations. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

At #ASCO26, Karun Neupane, MD (@KarunNeupaneMD), and Jeff Johnson, MD, joined @PatrickHwuMD to discuss receiving prestigious Young Investigator Awards from @ConquerCancerFd. Their funded research focuses on AI-guided treatment optimization in multiple myeloma and ctDNA-guided decision-making in penile squamous cell carcinoma. Congratulations to these outstanding early-career investigators advancing the future of cancer care. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

Live from his poster at #ASCO26, Andreas Saltos, MD, shares research exploring treatment strategies for advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitor therapy. #MoffittASCO26

[Dr. Patrick Hwu @PatrickHwuMD]

I caught up with Dr. Nikhil Khushalani of @Moffittnews about his work in melanoma and other skin cancers.

His research focuses on developing new treatment options for patients with melanoma, including uveal melanoma and melanoma that has spread to the brain.
#ASCO26 #MoffittASCO26

[W. Gregory Sawyer @ProfGregSawyer]

Want to learn more about what we are doing in the Department of BioEngineering at @MoffittNews? Stop by booth #14012 today at #ASCO26!

[Jonathan Zager, MD @jzager99]

Lacey Mead presenting results after neoadjuvant IO for Merkel cell carcinoma, and how well the patients do. Demonstrating an overall response rate of 75% and complete major path response of 60%. Great work. More to come as we do more with neoadjuvant and MCC @ASCO @MoffittNews

[Moffitt Cancer Center @MoffittNews]

We caught up with Brandon Blue, MD (@DrBlueMD), after his session at #ASCO26 to discuss key takeaways from emerging research in hematologic malignancies and why these findings matter for patient care and future directions in the field. #MoffittASCO26

[Dr. Patrick Hwu @PatrickHwuMD]

Stopped by Dr. Jonathan Zager’s (@jzager99) poster at #ASCO26 to discuss research exploring a sequential treatment approach in metastatic uveal melanoma, from regional therapy to systemic approaches designed to improve care. #MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

Happening live at #ASCO26, Sarimar Agosto Salgado, MD (@AgostoSarimar), discusses differentiated thyroid cancer care, highlighting emerging treatment strategies and practical evidence helping inform clinical practice.

Key takeaways:
•Redifferentiation restores RAl avidity using short-course MAPK pathway inhibitors (4-6 weeks), offering a fundamentally different strategy from long-term kinase inhibitor therapy - limited drug exposure, fewer cumulative toxicities, and potential for durable responses in selected cases.

•RAS-mutant and follicular-phenotype tumors are the best candidates - they retain more thyroid differentiation gene expression. BRAF V600E tumors respond less consistently but benefit from combined BRAF + MEK inhibition over MEK alone.

•Standardized protocols, prospective registries, and collaborative trials are essential to guide the appropriate candidate selection and obtain long-term safety outcomes.

#MoffittASCO26

[Moffitt Cancer Center @MoffittNews]

Could personalized vaccine approaches help shape the future of breast cancer treatment? Hatem Soliman, MD, will share research at #ASCO26 evaluating a personalized dendritic cell vaccine strategy for high-risk triple-negative breast cancer following neoadjuvant therapy. #MoffittASCO26 @ASCO